[ad_1]
Nader Pourhbadan, CEO of CytoDyn Inc. (OTCMKTS: CYDY), told Proactive Investors that the FDA had convened a face-to-face meeting to discuss and eventually finalize the biotech company's protocol for a trial of the flagship drug, leronlimab, in as a single treatment for HIV patients.
Dr. Pourhbadan is also interested in the stagnant course of society's action and the question of whether it poses a risk.
Source link
